Navigation Links
ThromboGenics NV Announces Business Update and Half Year Results 2009
Date:8/27/2009

by the Efficacy Safety Monitoring Board.

The Phase II trial is an active (enoxaparin)-controlled, dose-escalating, multicenter, prospective, randomized, open label trial evaluating TB-402 for the prophylaxis of DVT after knee surgery. Interest around TB-402, which is given as a single injection post surgery and has several weeks of activity, is due to its potential to overcome the major drawbacks, such as spontaneous bleeding and the need for extensive patient monitoring, associated with current anti-coagulant therapy.

ThromboGenics and its development partner BioInvent plan to engage in discussions with potential partners for TB-402.

During this period, additional data from the earlier successful Phase I studies were presented at the XXII Congress of the International Society on Thrombosis and Haemostasis (ISTH) on July 15, 2009 in Boston by Professor Peter Verhamme from KULeuven.

    TB-403 (RG7334) - Novel anti-cancer agent partnered with Roche

    - Partnership with Roche continues to run smoothly with TB-403
      Phase Ib enrolment completed recently

In June 2008, ThromboGenics and its co-development partner BioInvent signed a strategic alliance deal with Roche for its novel anti-cancer agent, TB-403 (anti-PIGF). The partnership continues to run smoothly and enrolment for the Phase Ib trial was completed in the second quarter of 2009. This Phase Ib trial is assessing TB-403's tolerability, pharmacokinetics and pharmacodynamics in patients with advanced cancer.

The results from this trial are currently planned to be presented at a scientific conference later this year.

In January 2009, ThromboGenics and BioInvent received their first success fee from Roche based on the successful transfer and implementation of technology and process development for TB-403 production. ThromboGenics received EUR3 million (60%) of the overall EUR5 million
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ThromboGenics NV: Business Update
2. ThromboGenics Announces Business Update and 2008 Full Year Results
3. ThromboGenics and BioInvent Start Phase II Trial of TB-402, a Novel, Long Acting Anticoagulant for Deep Vein Thrombosis (DVT) Prophylaxis
4. ThromboGenics N.V.: Business Update
5. ThromboGenics Announces Half Year Results 2008
6. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
7. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
8. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
9. ThromboGenics N.V. - Business Update
10. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
11. ThromboGenics Announces 2007 Full Year Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... June 29, 2015  AACC, a global scientific ... through laboratory medicine, is pleased to announce that ... Chemistry , has increased to 7.9 in the ... places Clinical Chemistry in the top ... significant influence of the research it publishes on ...
(Date:6/29/2015)... ... June 29, 2015 , ... The StampedeCon 2015 Big ... the fourth year in a row, will bring top technology professionals to St. Louis. ... the intersection of data and technology. The event is proudly sponsored by DataStax, Cisco, ...
(Date:6/26/2015)... Mass. , June 26, 2015  SeraCare ... vitro diagnostics manufacturers, today announced that it has ... with the National Cancer Institute (NCI), part of ... materials and positive controls for cancer assays.  The ... mix and accurately quantitate control DNA biosynthetics spiked ...
(Date:6/26/2015)... 2015  A San Francisco company, Pembient, recently announced ... rhino horn: beer in China ... In response to the emerging industry, two leading rhino ... of synthetic rhino horn.  The ... Rhino International (SRI) released a joint statement ...
Breaking Biology Technology:AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 2AACC's Journal, Clinical Chemistry, Continues to Have Significant Impact on Medical Testing, Healthcare 3StampedeCon Announces 2015 Agenda 2StampedeCon Announces 2015 Agenda 3SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 2SeraCare Life Sciences Signs CRADA with NCI to Advance Cancer Diagnostics 3Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2
... Roles as Vice Chairman of The Foundry and Advisor to ForSight ... ... Labs, MENLO PARK, Calif., Sept. 4 Morgenthaler Ventures, (http://www.morgenthaler.com/ventures ... technology investments, today announced the,addition of Hank Plain as partner in ...
... PRINCETON, N.J., Sept. 4 Medarex, Inc.,(Nasdaq: MEDX ... at the Bear,Stearns 20th Annual Healthcare Conference at 9:00 ... is being held at The Grand Hyatt,New York in ... and,will be available for replay through the Webcast page ...
... Paves the Way for the Phase III Clinical ... Commercialization of THR-100 in Developing ... NV (Euronext,Brussels: THR), a biotechnology company focused on ... technology transfer to Bharat,Biotech International Limited (Hyderabad, India) ...
Cached Biology Technology:Hank Plain Joins Morgenthaler Ventures as Partner 2Hank Plain Joins Morgenthaler Ventures as Partner 3Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 2ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 3ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent 4
(Date:6/30/2015)... 30, 2015 To bolster its efforts and commitment ... announced today the addition of two new team members. ... advisor and David Raviv will act as head ... Corp.,s commitment to providing the most secure solutions for the ... co-founded Layer 7 Technologies, a provider of security and management ...
(Date:6/30/2015)... , June 30, 2015 Genisphere ... as CEO to help further develop Genisphere,s therapeutics capabilities ... partnering experience, having spent much of the last 25 ... Amgen, Baxter Bioscience, and Johnson & Johnson. Tom started ... Technology and Biotech Corporate Finance. He graduated from Dartmouth ...
(Date:6/29/2015)... 24, 2015 Research and ... "Latin America Biomedical Sensors Market - Growth, Trends ... The Latin America Biomedical Sensors market is estimated ... 2.04% over the period 2014-2020 The near ... the genetic formulation of each individual. These sensors can ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3Latin America Biomedical Sensors Market Report 2015-2020 2
... CITY While researching new ways to stop the ... Health Sciences Center, have discovered a compound that has ... appears in the journal Gene Regulation and Systems Biology. ... clinical trials, successfully stopped normal cells from turning into ...
... gel electrophoresis" Most teenagers wouldnt have a clue what ... Trigiano knows the protocol inside and out. When Andrew ... the University of Tennessee, was looking for an interesting ... differences in popular brands of Easter egg dyes, Trigianos ...
... will help archeologist Bill Middleton peer into the ancient ... hyperspectral data will help build the most accurate and ... state of Oaxaca, where the Zapotec people formed the ... you ask someone off the street about Mexican archeology, ...
Cached Biology News:Chemical compound prevents cancer in lab 2DNA fingerprinting simplified 2Archaeologist uses satellite imagery to explore ancient Mexico 2Archaeologist uses satellite imagery to explore ancient Mexico 3
Mouse Laminin-1 MAb (Clone AL-3)...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
IEX-1 S/L (H-20)...
WIF-1 (N-20)...
Biology Products: